Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
- 1 February 1999
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 53 (3) , 209-215
- https://doi.org/10.1023/a:1006134702484
Abstract
Purpose: To comparatively analyse the risk of recurrence at given times after surgery for breast cancer patients receiving or not receiving adjuvant CMF. Patients and methods: A total of 1452 node...Keywords
This publication has 20 references indexed in Scilit:
- Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancyBreast Cancer Research and Treatment, 1996
- Angiostatin induces and sustains dormancy of human primary tumors in miceNature Medicine, 1996
- Steps in tumor metastasis: new concepts from intravital videomicroscopyCancer and Metastasis Reviews, 1995
- Contralateral breast cancer: annual incidence and risk parameters.Journal of Clinical Oncology, 1995
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Assessing the impact of adjuvant therapy on cure rate for stage 2 breast carcinomaBritish Journal of Cancer, 1993
- Logistic Regression, Survival Analysis, and the Kaplan-Meier CurveJournal of the American Statistical Association, 1988
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958